National Cancer Institute U.S. National Institutes of Health | www.cancer.gov
SPORES Logo - Translational Research, Clinical, Pre-Clinical, Basic, Pre-Clinical SPOREs - Specialized Programs of Research Excellence
Home Organization of the OSB Organ-Specific SPORE Programs Information for the Public Patient Advocate Research Team Information for Applicants Address and Directions IntraSPORE Communications  

[ SPOREs: Brain | Breast | GI | GU | GYN | Head and Neck | Leukemia | Lung | Lymphoma | Myeloma | Ovarian | Pancreatic | Prostate | Skin ]

Myeloma SPOREs

Multiple myeloma, a disease of white blood cells, will claim 11,310 lives in the year 2006, according to the estimates by the American Cancer Society. Another 16,570 new cases will be diagnosed in the same year. The five-year relative survival rates improved only slightly during the last 30 years and are still at the low 30% level. The first solicitation for Myeloma SPORE applications was announced in the year 2001, applications were reviewed in the year 2002 and the first award given in 2003.

To view the associated abstract, click on the name/address below.

Kenneth Anderson, M.D.
Chief, Division of Hematologic Neoplasia
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
44 Binney Street
Boston, MA 02115
Tel: (617) 632-2144
Fax: (617) 632-2140

For more information on this specific SPORE's institution, please visit: http://www.dhfcc.harvard.edu/spores/

 

National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov